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Abstract: 
Calmodulin antagonists have been shown to enhance DNA damage 
induced by a variety of chemical and physical agents, including 254 
nanometer (nm) ultraviolet (UV) light in normal human fibroblasts. These 
studies have suggested the existence of a calmodulin mediated process of 
DNA repair that is a potential target for the development of new 
therapeutic approaches for neoplastic diseases We examined the 
interaction of calmodulin antagonists and UV irradiation against murine 
lymphoblastic leukemia (LI210) and human T-cell lymphoblastic leukemia 
(CEM) cell lines. 
Cells were grown in suspension culture and were exposed to 10 J/m2 of 
254 nm UV light in sterile vessels. Exposure was followed by incubation 
with varying concentrations of the calmodulin inhibitors trifluoperazine or 
melittin . Cells were counted daily and degree of inhibition of cellular 
proliferation was examined. Dose response relationships for LI210 and 
CEM cells were established for the calmodulin antagonists and UV exposure 
using measurements of cellular proliferation. 
Our results demonstrated that recovery from UV irradiation was not 
significantly inhibited in the presence of calmodulin antagonists in either 
of the cell lines studied, implying that calmodulin is not involved in the 
repair of UV induced pyrimidine dimers. 
* 
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Introduction: 
In recent years the existence of a calcium messenger system as a 
fundamental means of regulating cellular functions has been well 
established. The large gradient between extracellular Ca++ concentrations 
(~1mM) and intracellular free calcium concentration (-100-200 nanomolar) 
is maintained by a complex series of homeostatic mechanisms. Small 
changes in intracellular calcium concentrations affect a wide variety of 
cellular functions as part of a “second messenger" system analagous to the 
cyclic adenosine 3‘,5’-monophosphate (cAMP) messenger system. A small 
protein, calmodulin, plays an important role in the calcium messenger 
system.1 
Calmodulin was discovered in the late 1960s and has been discussed 
extensively in many review articles in recent years.3 A5A7A9 it is a 
small (148 amino acid, molecular weight 16,700), acidic, heat stable 
protein present in all eukaryotic cells examined to date. It has been highly 
conserved across evolutionary lines, and only subtle differences have been 
identified in the sequences of calmodulins purified from species which are 
widely separated phylogenetically, a factor which implies that calmodulin 
is part of a regulatory system common to all eukaryotic cells. 
Each molecule of calmodulin has four structurally similar domains, 
each of which can bind a single Ca++ ion in response to changes in the 
intracellular calcium concentration. The binding of Ca++ to calmodulin 
produces conformational changes, which allow the specific interaction of 
calmodulin with a number of target proteins. Activity of the target proteins 
may be altered in this manner, causing changes in a variey of cellular 
functions. 
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Strict criteria for the designation of calmodulin-dependent processes 
have been set forth by Cheung, one of the first to describe the protein.10 
Enzymes which have met the stringent criteria include ones involved in 
cyclic nucleotide metabolism1 \ protein phosphorylation12, energy 
metabolism13 and other key cellular functions. The list of processes in 
which calmodulin has been implicated as a regulator is much longer, and 
includes such processes as DNA synthesis14, cell growth and 
differentiation15, and mictrotubular function16 which are important in 
consideration of the role calmodulin may play in neoplastic cells. 
A large number of compounds have been demonstrated to be 
calmodulin antagonists. (For reviews, see 17,18,19) jne phenothiazine 
family of compounds, used clinically as anti-psychotics, were the first 
compounds to be used experimentally as calmodulin inhibitors. A wide 
variety of compounds from different structural classes have subsequently 
been shown to have calmodulin antagonist activity, including the 
napthalenesulfonamide, or “W" compunds. Known calmodulin antagonists, 
however, suffer from a lack of specificity, and are known to exert effects 
on cellular components such as membranes and hormone receptors which are 
not directly linked to their effects as calmodulin antagonists. This 
complicates their use as tools for the elucidation of calmodulin-dependent 
processes. Structure-activity analysis of calmodulin inhibitors by 
Prozialeck and Weiss have defined the essential stuctural features for 
calmodulin antagonism to include a large hydrophobic region composed of at 
least two aromatic rings and an amino group separated from the hydrophobic 
region by a side chain of at least four atoms.20 
The large amount of research which examines the role of calmodulin 
in neoplasia has been discussed in several reviews.15,2! ,22,23 Hait and 
4 
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Lazo have summarized a large number of investigations in which calmodulin 
antagonists have been shown to inhibit cell growth and induce 
cytotoxicity.23 Most experiments have involved work with malignant cell 
lines in culture, although some in vivo animal experiments have been 
reported and clinical trials are currently in progress. Many of the studies 
summarized demonstrated a good correlation between the concentration of 
calmodulin inhibitors required to inhibit clonogenicity and the concentration 
required to inhibit calmodulin in cell free assay systems. 
Several lines of research address the role which calmodulin may 
play in neoplastic cells. Increased concentrations of calmodulin have been 
reported in some, but not all studies in which the calmodulin content of 
hyperproliferative and malignantly transformed cells has been compared to 
that in controls.15 Cell-cycle specific elevations in calmodulin content have 
been reported, and progression through the cell cycle has been shown to be 
inhibited by calmodulin antagonists.24-25 However, the capacity of 
calmodulin to alter protein activity by phosphorylation leaves open the 
possibility that calmodulin may specifically affect neoplastic cells via the 
regulation of as yet unidentified processes. As mentioned previously, data 
implicates calmodulin as a regulator of many more processes than are 
currently definitively categorized as calmodulin-dependent. 
The following review attempts to summarize the data linking 
calmodulin to the fundamental cellular process of DNA repair. 
Experiments have been conducted using physical factors known to induce 
DNA damage, such as ultraviolet (UV) light, x-irradiation, and 
hyperthermia, in conjunction with calmodulin antagonists. In addition, 
many chemotherapeutic agents currently in use are thought to exert their 
therapeutic effects by inducing DNA damage, and experiments have been 
- 
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performed which examine their interactions with calmodulin antagonists. 
The potentiation of therapeutic effects produced by DNA damage in 
malignant cells may be mediated by the inhibition of DNA repair processes. 
Thus, the findings that calmodulin antagonists may be regulators of DNA 
repair indicate that there may be a role for calmodulin antagonists as 
components of new regimens in anti-neoplastic therapy. 
Using Chinese hamster ovary (CHO) cells growing exponentially in 
culture, Chafouleas, Bolton, and Means examined the effects of members 
of the napthalenesulfonamide class of calmodulin inhibitors in combnation 
with bleomycin. 26 Bleomycin, an anti-tumor antibiotic, is thought to act 
by fragmenting DNA. The authors noted that when CHO cells were treated 
with non-toxic concentrations of bleomycin in combination with non-toxic 
concentrations of the calmodulin inhibitor W-13, a dramatic decrease in 
the fraction of surviving cells was noted. There was a dose-dependent 
decrease in the surviving fraction of cells as the concentration of W-13 
was increased. This effect was not noted when compound W-12 , an analog 
of W-13 which is not active as a calmodulin antagonist, was used. The 
combination of W-12 and bleomycin did not cause greater cytotoxicity 
than did bleomycin alone. Inhibition of recovery from bleomycin induced 
potentially lethal damage was also noted with trifluoperazine. 
As they noted these effects with calmodulin Inhibitors from two 
different structural classes, the authors postulated that their results 
were due to the inhibition of a calmodulin dependent DNA repair process. 
They noted a decrease in the nucleoid sedimentation migration rate, a 
measure which has been shown to correlate with DNA damage, in nucleoids 
which had been prepared from cells treated with bleomycin. In cells 
allowed to recover after exposure to bleomycin in either fresh medium or 
- 
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medium to which the inactive calmodulin inhibitor W-12 was added, 
recovery of the nucleoid sedimentation ratios to control levels were noted. 
However, when the cells were treated with the calmodulin inhibitor 
W-13 after exposure to bleomycin, the nucleoid sedimentation migration 
ratio was much lower than that of the control, at a level approximately 
that of the cells treated with bleomycin alone, without the oppurtunity for 
recovery. The authors concluded that DNA repair had not taken place in 
presence of the calmodulin antagonist W-13, but had occured when the 
inactive congener W-12 was present. 
Chafouleas and his colleagues also performed experiments on E. 
Coli.26 Unlike eukaryotes, E. Coli has not been shown to contain 
calmodulin. The authors found that W-13 did not potentiate DNA damage 
induced by bleomycin in this experimental system, providing additional 
support for their contention that the observed potentiation of bleomycin 
induced cytotoxicity was due to the inhibition of calmodulin 
Lazo, Hait and their colleagues also studied the effects of calmodulin 
antagoinsts in combination with bleomycin, using other experimental 
systems.27.28 Using L1210 murine leukemia cells, they demostrated 
enhancement of cytotoxicity when calmodulin antagonists were 
administered with bleomycin. These results were noted when calmodulin 
antagonists from a variety of different structural classes, the 
napthalenesulfonamide W-7, the phenothiazines trifluoperazine and 
chlorpromazine, the diphenylbutylpiperidine pimozide, and the peptides 
melittin and mastoporan, were used. The potentiation of bleomycin induced 
cytotoxicity was not noted when the napthalenesulfonamide W-5 and the 
phenothiazine chlorpromazine sulfoxide, which are not active as 
calmodulin antagonists, were used. 
. 
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Lazo and his associates further characterized the interaction of 
calmodulin inhibitors and bleomycin with human 5K-OV ovarian carcinoma 
cells, A-253 head and neck squamous carcinoma cells, and human 
hematologic stem cell colonies.29 The authors demonstrated a dose 
dependent enhancement of bleomycin induced cytoxicity in the 5K-0V and 
bone marrow progenitor cells using the calmodulin inhibitors 
chlorpromazine, melittin, and pimozide. However, they noted no such 
enhancement in the A-253 cell line, with is more sensitive to bleomycin 
than the other cell lines studied. 
In addition to noting the enhancement of cytotoxicity, Lazo, Hait and 
co-workers directly examined the effects of bleomycin and calmodulin 
antagonists on DNA.27 Using alkaline elution techniques to examine DNA 
from the LI210 cells, the authors noted an incresed number of DNA breaks 
in cells treated with bleomycin in conjunction with pimozide when 
compared to cells treated with bleomycin alone. DNA from cells treated 
with pimozide alone did not have an increased numer of breaks when 
compared to DNA from untreated cells. In a cell-free system using 
plasmid DNA, the authors noted no potentiation of bleomycin induced DNA 
breakage with the addition of pimozide. 
Lazo, Hait, et. al. concluded that the calmodulin antagonist mediated 
augmentation of bleomycin induced cytotoxicity was secondary to 
increased damage to the cellular DNA. This increased damage could have 
been a direct effect of the combination, or an indirect effect mediated by 
inhibition of DNA repair mediated by inhibition of calmodulin, as suggested 
by Chafouleas, Bolton, and Means.26 Although the concentrations of 
calmodulin antagonists required to enhance cytotoxicity are similar to the 
concentrations required to inhibit calmodulin, the lack of specificity of 
- 
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currently utilized calmodulin antagonists makes it difficult to 
definitively define the role of calmodulin in these processes.29 
Nonetheless, the observed potentiation of bleomycin induced DNA damage 
is clearly consistent with inhibition of DNA repair mechanisms by 
calmodulin antagonists. 
Based on the observed in vitro potentiation of bleomycin induced 
cytotoxicity by calmodulin antagonists, a Phase HI study using 
trifluoperazine in combination with bleomycin was conducted. Patients 
with a variety of malignancies, including Mycosis Fungiodes and 
gynecologic malignancies, were enrolled in the study. Although 
neuropsychiatric side effects and other toxicities were noted, several 
patients had measurable responses to the experimental regimen, and 
further clinical evaluation seems merited.30 
In an attempt to further examine the hypothesis that calmodulin 
antagonists inhibited DNA repair processes, Lazo, Hait et.al. also treated 
cells with calmodulin antagonists in combination with other agents known 
to cause repairable DNA damage. Using calmodulin antagonists in 
combination with x-irradiation and the chemotherapeutic agent etoposide, 
the authors were unable to demonstrate cytotoxic augmentation in LI210 
cells.27 
The absence of a synergistic effect between calmodulin antagonists 
and X-irradiation was subsequently demonstrated by Ridinger and his 
colleagues in experiments utilizing a murine mammary carcinoma cell line. 
The investigators found that addition of the calmodulin inhibitor W-13 to 
cell cultures prior to X-irradiation had no effect either on cell survival, 
the amount of DNA damage induced, or the ability of the cells to repair the 
X-ray induced DNA damage.31 
. 
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George and Singh, however, noted different effects in in vivo 
exDeriments using x-rays In combination with calmodulin antagonists. 
Using a transplantable murine fibrosarcoma, they found that the 
phenothiazines promethazine, prochlorperazine, and trimeprazlne did not 
delay tumor growth. However, when the same compounds were 
administered to mice prior to x-ray treatments, potentiation of the tumor 
growth delay produced by x-irradiation alone was noted,32 
The potential use of hyperthermia in cancer therapy has attracted 
Increased attention in recent years, as the increased sensitivity of tumor 
cells over that of normal cells has become recognized. Hyperthermia has 
multiple effects on the cell, including effects on DNA synthesis and 
replication.33 Specific effects on DNA repair have been suggested by 
Corry et. al., who noted potentiation of cytotoxicity, as well as inhibition 
of DNA repair mechanisms, in CHO cells treated with hyperthermia in 
combination with ionizing radiation.34 Later work by Meyn, Corry and 
colleagues showed that treatment of CHO cells with bleomycin at 43 *C 
caused significantly greater cytotoxicity than treatment with identical 
concentrations of drug at 37 ’C 35 Alkaline elution analysis revealed that 
the enhancement of cytotoxlcty at the higher temperature was not 
explicable by an increase in the degree of DNA breakage. Instead, the 
authors demonstrated that the DNA repair of bleomycin induced DNA 
damage was rendered less effective by hyperthermia 
Using Reuber H35 rat hepatoma cells and N3A neuroblastoma cells, 
Wlegant and his colleagues demonstrated significant potentiation of 
hyperthermic cytotoxicity when cells were simultaneously treated with 
trifluoperazine.36 Concentrations of trifluoperazine (5um and 10pm) 
were used which had been shown to be noncytotoxic alone. With the 
■ 
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concurrent administration of hyperthermia (43° C for 1 hour) however, the 
same doses of trifluoperazine were found to produce cytotoxic 
enhancement Similar results were obtained for both the neuroblastoma 
and hepatoma cell lines. In vivo studies by George and Singh found that 
treatment of a transplantable murine fibrosarcoma with non-toxic doses 
chlorpromazine prior to treatment with hyperthermia delayed tumor 
growth to a greater degree than did hyperthermia alone.37 
Given that interactions of bleomycin and hyperthermia, hyperthermia 
and calmodulin antagonists, and bleomycin and calmodulin antagonists 
have all been shown to effect enhanced cytotoxicity, it is not suprising 
that combinations of all three agents have shown further enhancement. 
Smith, Mircheva. and Bleehen, using murine EMT6 mammary tumor cells, 
investigated the combination of bleomycin, hyperthermia (44 °C) and 
trifluoperazine. 38,39,40 setting the degree of cytotoxicity (as measured 
by clonogenicity) produced by bleomycin alone as 1.0, they found that the 
addition of a non-toxic dose of trifluoperazine alone enhanced the degree 
of cytotoxicity by a factor of 1.3 while the addition of a non-toxic 
exposure of hyperthermia enhanced by a factor of 19. The combination of 
the exposures of bleomycin with trifluoperazine and hyperthermia 
produced enhancement by a factor of 112, a greater than additive effect. 
Unfortunately, the authors did not present data showing the effect of 
hyperthermia and trifluoperazine in combination without concurrent 
bleomycin administration. 
Smith, Mircheva, and Bleehan examined the DNA damage caused by 
these therapeutic combinations by using both the nucleoid sedimentation 
and alkaline denaturatlon assays. The nucleoid sedimentation assay 
preferentially detects single strand breaks in DNA, whereas the alkaline 
' 
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denaturation assay detects both phosphodiester bond breaks in the DNA as 
well as alkali labile lesions. The alkali labile lesions are 
apyrimidinic/apurinic sites (AP sites) where bases are missing from the 
DNA molecule without frank breaks of the DNA strand. Analysis of results 
from the two different assays of DNA damage showed that while 
hyperthermia diminished the repair of bleomycin induced DNA damage by 
depressing the repair of both single-strand breaks (ssbs) and AP sites, 
trifluoperazine selectively interfered with the repair of AP sites. As the 
calmodulin antagonist trifluoperazine and hyperthermia appear to inhibit 
the repair of DNA damage by separate mechanisms, the potential for a 
synergistic enhancement of the cytotoxic effect of bleomycin is 
established. 
Charp and Regan examined the effects of the calmodulin inhibitor 
trifluoperazine in combination with 254 nm UV light on normal human skin 
fibroblasts in culture.41 Having prelabeled the cells with 3H thymidine, 
20 Joules/meter2 (J/m2) of 254 nm UV light was administered to initiate 
the formation of cyclobutane pyrimidine dimers. Immediately after UV 
exposure, either 25pM of trifluoperazine or a control solution was added, 
and the percentage of pyrimidine dimers remaining was followed by two- 
dimensional paper chromatographic analysis of hydrolyzed DNA from the 
exposed fibroblasts. 
After 24 hours of post-exposure Incubation, the authors noted that 73% 
of the pyrimidine dimers remained in the cells treated with 
trifluoperazine as compared to 53.5% remaining in the cells treated with 
control solution only after UV exposure. This 26% difference was 
significant, however, no significant difference was noted In the DNA 
prepared from ceils either 3 or i 2 hours post-exposure. 
' 
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The authors tried to determine which step of the DNA repair process 
was affected by trifluoperazine by examining its effects with other assay 
systems for DNA repair. Using bromodeoxyuridine photolysis, normal 
function of exonuclease and polymerase activity was demonstrated in the 
presence of trifluoroperazine. These results led the authors to conclude 
that calmodulin antagonists specifically acted upon the incision step of 
repair. Additional data obtained by inhibiting polymerase activity with 
cytosine-arabinoside supported this conclusion. 
Kwok and Twentyman examined the effects of a number of cytotoxic 
chemotherapeutic agents in combination with trifluoperazine.42 They used 
small spheroids of murine EMT6/Ca/VJAC mammary tumor cells treated 
with bleomycin, CCNU, nitrogen mustard, and x-irradiation and exposed to 
non-toxic concentrations of trifluoperazine for 24 hours after exposure to 
the cytotoxic agents. No difference was noted in the surviving fraction of 
these cells after the 24 hour exposure to trifluoperazine when compared 
to the surving fraction measured immediately after exposure to the 
cytotoxic agent, without exposure to the calmodulin antagonist. The 
authors were unable to demostrate an effect of calmodulin antagonists on 
recovery from potentially lethal DNA damage in the experimental system 
used. 
Darkin and his colleagues found that DNA isolated from PY815 cell 
nuclei was damaged after treatment with the DNA intercalating agent m- 
AM5A 43 The DNA was resealed when the nuclei underwent subsequent 
incubation in drug-free medium. However, the degree of repair was 
significantly inhibited when incubation took place in the presence of 
chlorpromazlne, Indicating that the DNA repair may have been calmodulin 
mediated. 
, 
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Interactions between doxorubicin and related anthracycline 
compounds, compounds felt to work by intercalation into and disruption of 
nucleic acids, with calmodulin antagonists have been explored by 
Ganapathi and his associates.44*45 Much of their work has involved the use 
of a doxorubicin-resistant P388/DOX murine leukemia line, where they 
have demonstrated up to a TOO fold increase in anthracycline induced 
cytotoxicity with the use of trifluoperazine. The mechanisms underlying 
the resistance of these cells to doxorubicin and other compounds are 
unclear, as is the entire phenomenon of multidrug resistance (For a recent 
review, see 46). Cytotoxic enhancement was also noted in experiments 
with the non-resistant P388/5 cell line. These results were dose- 
dependent, and were noted with both trifluoperazine and chlorpromazine at 
concentrations appropriate to the potency of the two compounds as 
calmodulin antagonists 44 
In further experiments with the non-resistant P388/5 cell line, 
Ganapathi and his associates noted that calmodulin antagonists 
preferentially enhanced the cytotoxicity of strong DNA binding agents, 
including the chemotherapeutic agents dactinomycin and AM5A, in addition 
to the anthracyclines doxorubicin and daunorubicin.47 In contrast, they 
did not note enhancement of cytotoxicity when weakly DNA binding 
anthracycline analogs were used. The mechanism of cytotoxic 
enhancement in the sensitve P388/5 cell line is less well understood than 
in the resistant phenotype, where attention has been focused on 
differences in cellular uptake and retention of the anthracyclines.44*45 
However, the existence of cytotoxic enhancement of strong DNA binding 
agents from a variety of different structural classes by calmodulin 
■ 
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antagonists indicates that calmodulin may be involved as a regulator of 
the DNA damage and repair mechanisms involved. 
The studies linking agents which can induce DNA damage and 
calmodulin antagonists discussed above, are summarized below in Table 1. 
To expand the exploration and characterization of the effects calmodulin 
antagonists may have in combination with DNA damaging agents, we were 
interested in exploring their effects in combination with 254 nm UV light 
in malignant cell lines. The existence of synergism or augmentation of UV 
induced cytotoxicity by calmodulin antagonists would strengthen the case 
for the role of calmodulin as a mediator of DNA repair processes. 
The cyclobutane dimer formed by adjacent pyrimidine bases in DNA 
upon absorbtion of UV light in the 254 nm range is a well understood model 
of DNA damage, and has been described as the "classic test lesion" for the 
study of DNA repair.48 Once formed, the dimers block DNA replication and 
can result in cell death. Repair of damage involves the recognition of 
abnormality, the excision of the affected bases, usually along with 
adjacent nucleotides, and the replacement of the segment of DNA removed, 
using the complementary strand as a template. Deficiency in this repair 
mechanism, as occurs in the human disease Xeroderma Pigmentosa, results 
in increased incidence of cancer. Experimental work in E.Coli. has shown 
that even a single unrepaired dimer may prove lethal.48 As UV induced DNA 
damage and repair is especially well understood, work done with this 
experimental system stands a greater chance of allowing insights into the 
specific site in the DNA repair process at which calmodulin antagonists 
are effective. 
' 
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Table 1: Summary of studies using calmodulin antagonists In 
combination with physical and chemical agents which damage DNA 
DNA-dam aging Experimental Calmodulin Result Reference 
agent System Antagonist 
Bleomycin CHO cells W-13, TFP Enhancement 
noted 
26 
L1210 cells W-7.TFP, 
CPZ, PIM, 
Mel, Mas 
Enhancement 
noted 
27,28 
Plasmid DNA PIM No Enhancement 
noted 
27 
SK-OV cells CPZ,PIM,Mel Enhancement 
noted 
29 
A-253 cells CPZ, PIM, Mel No Enhancement 
noted 
29 
Bone marrow 
progenitor cells 
CPZ, PIM, Mel Enhancement 
noted 
29 
EMT.6 cell 
spheroids 
TFP No enhancement 
noted 
42 
EMT6 cells TFP Enhancement 
noted 
38,39 
X-irradiation 67 (P) cells W-13 No Enhancement 
noted 
31 
L1210 PIM, Mel No Enhancement 
noted 
27 
EMT6 cell 
spheroids 
TFP No Enhancement 
noted 
42 
in vivo murine 
fibrosarcoma 
PMZ, PPZ, TPZ Enhancement 
noted 
32 
Hyperthermia Neuroblastoma 
N3A cells, H35 
hepatoma cells 
TFP, 
Calmidazolium 
Enhancement 
noted 
36 
In vivo murine 
fibrosarcoma 
CPZ Enhancement 
noted 
37 
Bleomycin & 
Hyperthermia 
EMT6 cells TFP Enhancement 
noted 
38,39 
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Table 1 (continued): 
DMA-dam aging Experimental Calmodulin Result Reference 
agent System Antagonist 
Ultraviolet Normal human TFP Enhancement 41 
light fibroblasts noted 
(254 nm) L1210 cells TFP, Mel No Enhancement 
noted 
* 
CEM cells TFP No Enhancement 
noted 
* 
AMSA PY815 cell nuclei CPZ Enhancement 
noted 
43 
P388/S cells TFP Enhancement 
noted 
47 
Doxorubicin P388/5 cells TFP Enhancement 
noted 
47 
EMT6 cell TFP No enhancement 42 
spheroids noted 
Dactinomycin P388/S cells TFP Enhancement 
noted 
47 
CCNU EMT6 cell TFP No Enhancement 42 
spheroids noted 
Nitrogen EMT6 cell TFP No Enhancement 42 
Mustard spheroids noted 
Etoposide L1210 cells PIM, Mel No Enhancement 27 
noted 
*5ee Results section of this document. 
Abbreviations: TFP-Trlfluoperazine; CPZ-Chlorpromazine; PIM-Pimozide; 
Mel-Melittin; Mas-Mastoporan; PMZ-Promethazine; PPZ-Prochlorperazine; 
TPZ-Trimeprazine. 
/ 
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Materials and Methods: 
Cells: 
LI210 murine leukemia cells were maintained in suspension culture in 
Fisher's medium with 10% horse serum. CEM human lymphoblastic 
leukemia cells were maintained in suspension culture in RPMI medium 
with penicillin, streptomycin, and 10% horse serum. All cultures were 
stored in a 5% CO2 atmosphere in an incubator at 37' C. Cultures were 
passed at least twice weekly. 
Ultraviolet (UV) Light: 
UV exposure was provided by a Spectronics XX15A UV lamp containing a 
single BLE IT 155 254 nm. bulb. UV exposure was quantitated using a 
Schlumberger UV light meter and found to be approximately 10 J/m2 in 15 
seconds at the 70 cm. exposure distance utilized. 
Drugs: 
Trifluoperazine hydrochloride and melittin were obtained from the 
Sigma Chemical Co. (5t. Louis). Drug solutions were prepared no earlier 
than the day prior to the experiment using distilled H2O which had been 
sterilized by passage through 0.22um filter. Solutions were shielded from 
light and stored in the refrigirator. 
Studies of Cellular Proliferation: 
Cells growing in log phase were pipetted from culture flasks at an 
initial concentration of approximately 50,000/ml. Cells were placed in 
Petri Dishes or Nunc Plates at a depth of 0.25 cm. and exposed to UV light 
from a height of 70 cm.. During exposure, cells were placed on a Tektator 
rotating shelf at 60 r.p.m. 
M- 
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Drugs were added within 1 hour after UV exposure. Cells counts were 
made initially within 2 hours of exposure and daily thereafter using a 
Coulter Counter. 
Figures: 
Figures were prepared on a Macintosh computer using the Cricket Graph 
software package (Cricket Software, Philadelphia). On those figures 
which include error bars, error bars are not included for those points 
where the error is smaller than the marker for the data point. Growth 
curves included with the figures were plotted using the exponential 
regression fit feature of Cricket Graph. 
■ 
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Results: 
Figure 1 shows the response to LI210 cells to different lengths of 
exposure to 254 nm UV light. Each data point represents the mean of two 
replicates. The graphs demonstrate an exposure dependent relationship with 
increasing duration of exposure to UV. 
Figure 2 shows the response of LI210 cells to incubation with 
differing concentrations of trifluoperazine. Each data point represents the 
mean of two replicates. The graphs demonstrate that for doses of 1 pm, 
2pm, and 4pm, proliferation is not significantly inhibited, but that greater 
than 50% inhibition is noted with a dose of 8pm. 
Figure 3 shows the response of LI210 cells to differing 
concentrations of melittin. Each data point represents the mean of four 
replicates. These results demonstrated that melittin produced dose 
dependent inhibition of cell growth, with a dose of 0.25pm of melittin 
producing 45% inhibition when compared with the growth of control cells 
after 48 and 72 hours of incubation. 
This data allowed dose-response relationships for LI210 cells to the 
agents under consideration to be established. Using this information, a 15 
second exposure to UV, corresponding to a dose of 10 J/m2> was chosen. 
This dose produced consistently reduced cell growth of UV treated cells to 
approximately two-thirds the growth of control cells. 
Cells were incubated with varying concentrations of melittin and 
trifluoperazine after 10J/m2 UV exposure. Figures 4 and 5 show the growth 
curves for the LI210 cells treated with UV and post-exposure incubation 
with 2pm and 4pm concentrations of trifluoperazine, respectively. Each 
data point represents the mean of four replicates. The results show that 
. 
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the combination of trifluoperazine and UV exposure caused no greater 
reduction of cellular proliferation than did UV alone. 
Figures 6,7, and 8 show similar curves for LI210 cells treated with 
0.10pm, 0.25pm, and 0.50pm doses of melittin. Each data point represents 
the mean of four replicates. The figures show that the combination of 
treatment with UV and melittin had no greater effect on cellular 
proliferation than UV alone. In fact, at doses of 0.25pm and 0.50pm of 
melittin in combination with UV exposure, cells treated with both 
modalities had greater growth than that of controls, indicating a possible 
protective, rather than enhancing, effect of melittin in combination with 
UV induced DNA damage. 
The results of the combination of UV exposure and the calmodulin 
inhibitors trifluoperazine and melittin at 48 hours after UV exposure are 
summarized in Table 2. 
Table 2: Effects of Calmodulin Antagonists and 254 nm UV 
exposure on L1210 cell growth 
Drug and No UV exposure With UV exposure % of Control growth 
Concentration ± 2 s.d. + 2 s.d. in UV treated cells 
No Drug 100.0+10.9 68.5 + 4.6 69 
2pm TFP 98.9+ 2.9 88.2 + 3.3 89 
4pm TFP 115.6 ±10.2 75.4 + 7.9 65 
0.10pm Mel 71.0+ 5.9 55.3 + 5.2 78 
0.25pm Mel 60.1 t 7.2 65.2 + 5.2 108 
0.50pm Mel 43.8 ± 5.0 46.8 ± 7.0 107 
Results are expressed as increase over initial counts at 48 hours as a percentage of the increase 
of cells not exposed to either drugs or UV. 
CEM cells have a longer doubling time (approximately 24 hours) than 
L1210 cells (doubling time 10 to 12 hours) and this is reflected in the 
growth curves for the experiments with CEM cells. Figure 9 shows the 
- 
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effect of exposure to varying doses of UV light on the growth of CEM cells. 
The results demonstrate that the sensitivity of CEM cells to 254 nm UV 
light was similar to that observed with the LI210 cells, and accordingly 
the same 15 second length of exposure was chosen for subsequent 
experiments with the CEM cells. 
Figure 10 shows the effect of varying doses of trifluoperazine on 
the growth of CEM cells. The results show that for the CEM cells, incubation 
with 2pm, 4pm, and 8pm concentrations of trifluoperazine did not produce 
significant inhibition of growth, with a dose of 16pm producing 
approximately 50% inhibition of growth. The CEM cells demonstrated the 
same sharp increase in inhibition of cell growth near the IC50 as did the 
LI210 cells, but the CEM cell line required considerably higher 
concentrations of trifluoperazine for inhibition. 
Figures 11 and 12 show the growth curves for the CEM cells treated 
with UV in conjunction with 4pm and 8pm of trifluoperazine, respectively. 
The higher concentrations of trifluoperazine used with the CEM cells 
reflect the higher IC50 for trifluoperazine with the CEM cell line. Table 3 
summarizes the results at 48 hours after UV exposure. The graphs and 
Table 3 demonstrate that the no reduction in cell proliferation beyond the 
degree of inhibition produced by UV exposure alone was produced by the 
combination of UV and trifluoperazine. 
- 
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Table 3: Effects of Trifluoperazine and 254 nm UV light on CEM 
cell growth 
Drug and No UV exposure 
Concentration + 2 s.d. 
With UV exposure % of Control growth 
± 2 s.d. in UV treated cells 
No Drug 100.0 + 3.5 
4jim TFP 106.6 + 4.5 
8pm TFP 101.6+10.7 
Results are expressed as increase over initial 
of cells not exposed to either drugs or UV. 
68.4+13.9 68 
70.3 +13.5 66 
72.5+14.5 71 
counts at 48 hours as a percentage of the increase 
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Discussion: 
We used the LI210 murine lymphoblastic leukemia and CEM human T- 
cell lymphoblastic leukemia cell lines in our studies. Both grow readily in 
suspension culture. There has been extensive experience with the use of 
L1210 cells, and their responses to trifluoperazine and melittin, the 
calmodulin antagonists used in our studies, have been well characterized. 
49,50 our results confirmed earlier findings with respect to the sensitivity 
of LI210 cells to trifluoperazine and melittin, and established dose- 
response relationships for CEM cells to trifluoperazine. 
Many rodent cell lines are thought to be deficient in the repair of UV 
induced pyrimidine dimers. However, mouse L cells have been shown to 
excision repair mechanisms in place, although perhaps at reduced 
levels.51.52 As we found that the human CEM cell line had similar 
sensitivity to 254 nm UV light in our experiments, it is not probable that 
this factor introduced a bias into our results. The effect of exposure to 254 
nm UV light on proliferation of the LI210 and CEM cell lines in culture was 
characterized. 
In addition, use of the CEM line allows for more direct extrapolation 
to the potential use of UV light in combination with calmodulin antagonists 
for patients with human cutaneous T-cell lymphomas. Current treatments 
for these diseases include the use of 8-methoxypsoralen (8-MOP). 8-MOP, 
like the phenothiazines, is a photoactive tricyclic compound. It is thought to 
act by intercalating into DNA, and forming photoadducts which can 
covalently cross-link DNA when exposed to UV light in the ultraviolet A 
(320-400 nm.) range.53 Oral 8-MOP has been used for many years for the 
treatment of psoriasis and the plaque stage of cutaneous T-cell lympomas. 
After oral administration, the drug becomes photoactivated by the exposure 
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of cutaneous lesions to ultraviolet A. Recent work by Edelson and 
associates has shown that extracorporeal UV and 8-MOP exposure of 
affected lymphocytes from patients with disseminated cutaneous T-cell 
lymphoma can be efficacious in patients whose lesions are not accessible to 
cutaneous exposure. 54 
The potential for calmodulin antagonists to have similar clinical 
applications is possible. During their extended period of use as 
psychotherapeutic agents, the phenothiazines have become known as 
phototoxic compounds. Chlorpromazine and trifluoperazine, which have 
absorbtion maxima at 308 nm and 313 nm, respectively, have been shown to 
mediate these effects by both free radical and singlet molecular oxygen 
formation.55 The photoactivation of these compounds by near UV (UV-A) 
light has been shown to induce DNA damage in a number of experimental 
systems 56<57>58>59 This body of research has been conducted with near UV 
light however, while our experiments were conducted with far UV (UV-C) 
light, which, unlike near UV radiation, produces DNA damage in the form of 
pyrimidine dimers. Nonetheless, the potential existed that photoexcitation 
of trifluoperazine could be produced by the higher energy UV source used in 
our experiments. 254 nm UV exposure has been shown to induce covalent 
bonding of trifluoperazine to calmodulin.17 Thus, to avoid cytotoxic 
enhancement via a photochemical mechanism, we added phenothiazines to 
the culture medium after, rather than during exposure to the UV light. Our 
experiments did not examine a possible cytotoxic enhancement by a 
photosensitization mechanism, but rather by a DNA damage and repair 
mechanism. 
Our results failed to demonstrate that calmodulin antagonists 
enhanced the inhibition of cellular proliferation produced by short 
■ 
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wavelength (254 nm) ultraviolet light in the LI210 and CEM cell lines 
studied. These results do not confirm those earlier reported by Charp and 
Regan, who had demonstrated enhancement of UV induced DNA damage in 
normal human fibroblasts.41 The negative results obtained in our studies, 
unfortunately, do not clarify the confusing, somewhat contradictory 
literature which describes the interaction between calmodulin antagonists 
and physical and chemical agents capable of damaging DNA. This literature 
has been discussed in the introduction, and is summarized in Table 1. 
This review of the literature revealed that while several authors had 
not been able to demonstrate in vitro enhancement of X-irradiation induced 
cytotoxicity, 27,31,42 others were able to demonstrate in vivo 
enhancement.32 Multiple explanations are possible for these and the other 
seemingly contradictory results which make up the literature in this area. It 
has been demonstrated that the choice of different assay methods for 
results may introduce bias.60 The fact that even with the same 
investigators using the same techniques can obtain differing results with 
different cell lines was demonstrated by Lazo and associates in their 
studies on 5K-0V and A-253 cells.29 These differences in studies, 
introduced by choices of different experimental systems and assay 
techniques make it difficult to compare results. 
Additional problems arise in quantifying the interactions noted 
between biologically active agents. Although even a simply additive 
enhancement of cytotoxicity or DNA damage may be significant, it is 
important to distinguish the truly synergistic, greater than additive, 
therapeutic combinations. Berenbaum has suggested isobologram analysis as 
a means to distinguish between truly synergistic and simply additive 
. 
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effects 61, but most investigators do not subject their data to this means 
of analysis. 
Had our results demonstrated that calmodulin antagonists enhanced 
UV induced cytotoxicity, further studies could have been performed. The 
inhibition of cell growth measured in our studies could have been 
supplemented with clonogenicity studies. These would have aided in the 
differentiation between cells that were alive and not proliferating and cells 
that had actually been killed. 
Further studies would have been necessary to definitively attribute 
the effects noted on cellular proliferation to inhibition of DNA repair 
mechanisms. Other investigators have used serial measurements of the 
degree of DNA damage, using techniques such as alkaline elution, in order to 
assess DNA repair. Unfortunately, more precise techniques for the assay of 
DNA repair inhibition are not easily available, and the measure of biological 
end points is often used in the place of more specific assays.62 
The lack of specificity of calmodulin antagonists would have made it 
difficult to attribute positive results to the inhibition of calmodulin, as 
known calmodulin antagonists have a variety of non-calmodulin mediated 
pharmacologic effects. However, if similar results could have been 
demonstrated with calmodulin antagonists as structurally distinct as 
trifluoperazine and melittin at concentrations appropriate for calmodulin 
inhibition, a strong case for the involvement of calmodulin could have been 
made. Use of phenothiazines such as trifluoperazine oxide which are 
inactive as calmodulin inhibitors could have served as additional controls. 
Despite the negative results produced in our experimental system, 
however, enough data has been presented in other studies to warrant 
continued research to further delineate the role calmodulin and calmodulin 
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antagonists play in DNA damage and repair. Calmodulin antagonists such as 
trifluoperazine are already in wide clinical use for psychiatric disorders 
and have been demonstrated to be relatively well tolerated and non-toxic. 
They have potential to be useful in anti-neoplastic therapy, and have already 
begun to be used in combination with other agents in clinical trials.30 
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Figure 4: Response to UV and 2pm TFP 
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Figure 7: Response to UV and 0.25p Melittin 
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Figure 8: Response to UV and 0.50p. Melittin 
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Figure 9: CEM Response to UV exposure 
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Figure 10: CEN Response to Trifluoperazine 
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Figure 1 1: CEM Response to UV and 4pm TFP 
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Figure 12: CEM Response to UV and 8pm TFP 
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